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The Gene Ontology Consortium (GOC) is a community-based bioinformatics project that classifies gene product function
through the use of structured controlled vocabularies. A fundamental application of the Gene Ontology (GO) is in the
creation of gene product annotations, evidence-based associations between GO definitions and experimental or sequence-
based analysis. Currently, the GOC disseminates 126 million annotations covering >374 000 species including all the king-
doms of life. This number includes two classes of GO annotations: those created manually by experienced biocurators
reviewing the literature or by examination of biological data (1.1 million annotations covering 2226 species) and those
generated computationally via automated methods. As manual annotations are often used to propagate functional pre-
dictions between related proteins within and between genomes, it is critical to provide accurate consistent manual anno-
tations. Toward this goal, we present here the conventions defined by the GOC for the creation of manual annotation. This
guide represents the best practices for manual annotation as established by the GOC project over the past 12 years. We
hope this guide will encourage research communities to annotate gene products of their interest to enhance the corpus of
GO annotations available to all.
Database URL: http://www.geneontology.org
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Introduction
The Gene Ontology Consortium (GOC; http://www.geneon
tology.org) is a bioinformatics resource that serves as a
comprehensive repository of functional information about
gene products assembled through the use of domain-
specific ontologies (1). The project is a collaborative effort
working to describe how and where gene products act by
creating evidence-supported gene-product annotations to
structured comprehensive controlled vocabularies. The
Gene Ontology (GO) is a controlled vocabulary composed
of >38 000 precise defined phrases called GO terms that
describe the molecular actions of gene products, the
biological processes in which those actions occur and the
cellular locations where they are present. First developed in
1998 (2), the GOC project has grown to become an inte-
grated resource providing functional information for a
wide variety of species. As of January 2013, there are
>126 million annotations to >19 million gene products
from species throughout the tree of life. Of these there
are 1.1 million manually curated annotations, from pub-
lished experimental results, to 234 000 gene products. As
the GOC develops the standard language to describe func-
tion, it also defines standards for using these ontologies in
the creation of annotations. This article elaborates on the
methods and conventions adopted by the GOC curation
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teams for constructing annotations and serves as a guide to
new or potential annotators, and the biological community
at large, for understanding the requirements necessary to
create and maintain the highest quality GO annotations.
Overview of GO annotations
The goal of the GOC is the unification of biology by creat-
ing a nomenclature used for describing the functional char-
acteristics of any gene product, protein or RNA, from any
organism. There are two parts to a GO annotation: first, the
association asserted between a gene product and a GO def-
inition; and second, the source (e.g. published article) and
evidence used as the authority to make the assertion. The
GO is a set of highly structured directed acyclic graphs
(DAGs); its structure and content have been extensively
described elsewhere (2, 3). Here, we limit our presentation
to the GO term name (the phrase that is typically used
when discussing individual components of the ontologies,
often shortened to ‘GO term’), the GO definition, the text
string that explains the precise meaning of the GO term
and a numerical identifier called the GOID (examples used
in this guide are shown in Table 1). In addition, each term
can have multiple ontological relationships to broader
(parent) and more specific (child) terms (Figure 1 illustrates
how terms and relationships are represented in GO).
Although annotations are typically viewed as connec-
tions between a gene product and a GO term, it is import-
ant to stress that the GO term name is a surrogate for the
definition, and that the biological concept described by the
definition is really the core assertion being made by an
annotation. This is a subtle yet important point central to
understanding the power of the GO, one that is not always
appreciated by both annotators and consumers of GO an-
notations. As with a spoken language, the understanding
of its usage is based on shared definitions of the phrases
and definitions of the terms. Thus, annotating to the def-
inition is required to alleviate confusion if the names of
biological concepts or terminology used in the published
literature are ambiguous.
The source of the information used to make an anno-
tation includes both a specific reference, usually a pub-
lished scientific article represented by a PubMed identifier
(PMID), that describes the result of an experimental or
computational analysis on which the association was
based, and an evidence code (Table 2) that reflects the
type of experimental assay or analysis that supports the
association. Annotations can be asserted manually from
the literature by biocurators or computationally by auto-
mated methods. This article will focus on standards defined
by the GOC for manual curation. Computational annota-
tion methods and their guidelines have been reported
elsewhere (4).
Annotation format
GO annotations are recorded and supplied in a standard
tab-delimited file format called the Gene Associations
File (GAF, http://www.geneontology.org/GO.format.anno
tation.shtml). For each annotation, the GAF format con-
tains both required and optional fields, some of which
will be discussed below. The required fields are—the iden-
tifier of the gene product being annotated, the GOID of
the GO term associated with the gene product, an evidence
code and the reference (either a published article or a GOC-
specific internal reference) supporting the use of the GOID,
the aspect of the ontology (Molecular Function, Biological
Process, Cellular Component), the curation project that cre-
ated the annotation, the object type that is being anno-
tated (see below), the NCBI taxonomy database identifier
for the species of the gene product and the date the anno-
tation was created or modified. A sample annotation is
shown in Table 3.
Manual curation
Within the GOC, manual annotations are made by experi-
enced biocurators from a variety of annotation projects
including, but not limited to, the Saccharomyces Genome
Database [SGD, (6)], Mouse Genome Informatics [MGI, (7)],
WormBase (8), PomBase (9), FlyBase (10), ZFIN (11) and
UniProt (12). Manual curation typically encompasses two
approaches. The first involves reading relevant publications,
identifying the gene product(s) of interest, and ascribing
the reported experimental results to a GO definition
using an appropriate evidence code (Table 2). The second
involves inferring a gene’s role by manual examination of
its nucleic acid or protein sequence motifs, structure or
phylogenetic relationships. For consistent interpretation
of experimental results and sequence analysis, the GOC
has established annotation guidelines that are elaborated
below. GOC member projects (http://www.geneontology.
org/GO.consortiumlist.shtml) with assistance from other
groups engaged in advancing the representation of biolo-
gical function so that it can be presented in a straightfor-
ward but precisely defined form have developed these
guidelines. Over time these guidelines have evolved into
required standards for all manual annotations and have
been incorporated into validation tools used by the GOC
to maintain their quality and uniformity.
Gene product: Object of
annotation
The annotation object or molecular entity are those defined
by the Sequence Ontology [(13), http://www.sequenceontol
ogy.org] and includes complex, gene, gene_product,
.............................................................................................................................................................................................................................................................................................
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miRNA, ncRNA, protein, protein_complex, protein_struc-
ture, RNA, rRNA, snoRNA, snRNA, transcript, tRNA and poly-
peptide. While annotations are typically created for
chromosomal features, such as a gene for its protein or
ncRNA product, other types of objects can be annotated
including groups of gene products that make a complex.
The annotation object can be associated to a GO term
from one or more of the three aspects of the GO
(Molecular Function, Biological Process and Cellular
Component). A gene product is the most common object
of annotation, and all such objects require a stable identifier
such as those specified by sequence databases maintained
by European Bioinformatic Institute (EBI) and National
Center for Biotechnology Information (NCBI). Model
Organism Databases (MODs) also maintain unique identi-
fiers that often represent specific types of molecular entities
such as RNA transcripts that often do not have an identifier
from one of the archival repositories.
Approaching an article for curation
When experimental data on a gene product has been pub-
lished, the following guidelines can be used to identify the
relevant or annotatable pieces of information that may
generate GO annotation for that gene product.
(i) Identification of relevant articles describing a gene
product’s function is the essential starting point for
Figure 1. GO Term ‘leukotriene-A4 hydrolase activity’ [GO:0004463], one of the terms mentioned in the main text of the article,
as seen in AmiGO (16, http://amigo.geneontology.org). (a) Graphical view of the ontology structure showing the most granular
term ‘leukotriene-A4 hydrolase activity’ [GO:0004463] at the bottom (highlighted in red), and all its parent terms leading up to
the root node (‘molecular_function’ [GO:0003674]) at the top. Each box representing a GO term includes the GO identifier, and
the blue line connecting the terms represent the ontological relationship ‘is_a’ (implying that a child term is a subtype of the
parent term). (b) Alternate text display for viewing the ontology structure. ‘leukotriene-A4 hydrolase activity’ [GO:0004463] is
highlighted in red. Each child term is indented from its parent to indicate the depth of the tree. Apart from the GOID and GO
term, each row includes other pieces of information that are important to understand the ontology and the annotations to each
term. Starting from the left end of the row, the+ sign indicates that there are child terms for that node and clicking on the+ sign
opens the browser to display the child terms. Next the small icon ‘i’ indicates the term is related to its parent by an is–a
relationship (explained above). At the right end of the row in brackets is the total number of gene products annotated to
that term and all its child terms. (c) Term information relevant to making an annotation is highlighted in red, which includes the
GOID, Aspect of the ontology (Molecular Function), Synonyms and Definition of the term.
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making annotations. While PubMed is a typical start-
ing point for finding relevant articles, research in the
area of Natural Language Processing (NLP) provides
additional methods that can aid in the search for
curatable articles. More on NLP methods used for bio-
curation can be found in the reports from the
Biocreative workshops (14). Once an article has been
identified, biocurators must properly specify the ob-
jects of annotation including confirmation of the cor-
rect taxa. These details are often found in the
Methods section of the article, but unambiguously
determining species for annotation can be problem-
atic, particularly in vertebrate systems where ortholo-
gous gene names are shared among taxa. Further,
when multiple model organism systems are being
used simultaneously, the taxa of the genes being
investigated is not always specifically designated.
For example, Lin and Isaacson (15) studied axonal
growth regulation by netrin and slit proteins using
both mouse and rat cells. Two of the plasmids con-
taining slit coding sequences were acknowledged as
gifts and no reference to the species of origin was
provided. In this case, to determine the species the
sequences represent, the authors had to be contacted
to confirm that the sequences actually originated
from human, neither mouse or rat.
(ii) The Introduction section of the article will often pre-
sent previous knowledge about the gene product’s
function. If citations to original works are included
then the article can be used as a source of the infor-
mation and annotated using the evidence code (see
below) Traceable Author Statement (TAS). The use of
TAS evidence has decreased over time, as it is best
practice to go to the original article to capture the
annotation directly from experimental results. This
allows for clear attribution of an annotation to the
original experimental details. Thus, GOC strongly dis-
courages the continued use of TAS and recommends
replacing existing TAS annotations with those to the
published experimental results.
(iii) Annotations derived from experimental data are
most often found in the Methods and Results sections
or in the figure legends of articles. A biocurator can
efficiently receive an overview of the biological
Table 3. A sample annotation in the GAF 2.0 format
Column Content Required? Example
1 DB Required MGI
2 DB Object ID Required MGI:1350922
3 DB Object Symbol Required Cadps
4 Qualifier Optional NOT
5 GO ID Required GO:0006887
6 DB:Reference (jDB:Reference) Required MGI:MGI:3583730jPMID:15820695
7 Evidence Code Required IMP
8 With (or) From Optional MGI:MGI:3583931
9 Aspect Required P
10 DB Object Name Optional Ca2+-dependent secretion activator
11 DB Object Synonym (jSynonym) Optional CAPS1
12 DB Object Type Required Protein
13 Taxon(jtaxon) Required Taxon:10090
14 Date Required 20060202
15 Assigned By Required MGI
16 Annotation Extension Optional Occurs_in(CL:0000001)joccurs_in(CL:0000336)
17 Gene Product Form ID Optional UniProtKB:Q80TJ1
This table provides an example of an annotation from the Mouse Genome Informatics group (from February 2013). The Cadps protein
(MGI identifier MGI:1350922) was annotated by the MGI project to ‘exocytosis’ [GO:0006887], a term in the Biological Process ontology
indicated by ‘P’ in column 9. This annotation used the ‘NOT’ qualifier indicating the authors of PMID:15820695 (5) showed that this
protein is ‘NOT’ involved in ‘exocytosis’. The non-PMID reference number, MGI:MGI:3583730, is MGI’s internal identifier for the same
reference. The curators arrived at this annotation based on the phenotype of the Cadps mutant, which is indicated with the IMP
evidence code. The identifier of the allele (MGI:MGI:3583931) used in the experiment is captured in column 8 (WITH/FORM). In addition,
the annotation extension field (column 16) indicates the cell types where this protein (CL:0000001, primary cell culture or CL:0000336,
adrenal medulla chromaffin cell) was NOT found to be involved in this process (exocytosis). Finally, the last column represents the
UniProtKB identifier for the isoform of the mouse Cadps protein that was studied.
.............................................................................................................................................................................................................................................................................................
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context of the article from the Introduction section
and then, using the experimental data in the
Results section, create annotations with appropriate
supporting experimental evidence.
(iv) Authors often speculate on the role of the gene
product in the Discussion section based on the experi-
mental results they present. The authors may propose
a hypothesis that combines previous knowledge, new
findings from the current study and new ideas that
have not yet been experimentally verified. This infor-
mation is not suitable for an annotation assertion and
if used to create an annotation can be detrimental, as
these hypotheses have not been validated.
Manual curation using sequence
similarity data
Manual curation by biocurators includes the in-silico ana-
lysis of chromosomal features to infer a gene product’s role
and location. GO terms can be assigned to gene products
on the basis of sequence similarity using the evidence code
’Inferred from Sequence or structural Similarity’ (ISS) with a
custom reference, GO_Reference (GO_REF:0000024), as
described in the next section. Potential homologs are ini-
tially identified using sequence similarity search programs
such as BLAST. The significance of the sequence similarity is
then verified manually using a combination of sequence
resources and analysis tools, including phylogenetic and
comparative genomics databases such as Ensembl
Compara (16), INPARANOID (17) and OrthoMCL (18). In all
cases, biocurators validate each alignment to assess
whether similarity is appropriate to infer the gene prod-
uct’s function. While there is no universal definition for
the minimum requirements for similarity results, the signifi-
cance of a match is judged on a case-by-case basis by the
biocurator’s expertise. Although the similarity criteria
required to make these annotations are defined by the
annotating group, the GOC has established several rules
for making these assignments. They are as follows:
(i) Mandatory inclusion of a stable database identifier
that identifies the similar gene/gene product in the
‘WITH/FROM’ field (column 8 in Table 3)
(ii) The similar gene must be experimentally character-
ized; to avoid circular inferences, the GO term
should only be assigned if the similar gene/gene
product is, or can be annotated, with the same
term (or a more specific child term) using an experi-
mental evidence code (e.g. Inferred from Direct assay,
IDA; Inferred from Mutant Phenotype, IMP; Inferred
from Genetic Interaction, IGI, Inferred from Physical
Interaction, IPI; Inferred from Expression Pattern, IEP).
Annotations made with the NOT qualifier should not
be transferred.
Sequence characteristics can be used to infer GO anno-
tations for all three aspects of the ontology. However, care
should be taken when transferring biological process anno-
tations, as cellular processes and metabolic processes, for
example, may be more readily inferred from sequence
similarity than developmental processes which may be
species- or clade-specific
Use of GO reference
As mentioned above, manual curation does not always re-
quire a published reference to indicate the source of evi-
dence. Annotations can be inferred by biocurators by
analysis of the gene sequence or by combining direct
experimental evidence from multiple sources. In these situ-
ations, the citation is to a custom reference. These so-called
GO references describe the methods and procedures used
in creating such annotations. For example, GO_REF:
0000024 (http://www.geneontology.org/cgi-bin/references.
cgi#GO_REF:0000024), titled ‘Manual transfer of experi-
mentally verified manual GO annotation data to orthologs
by curator judgment of sequence similarity’, was created to
describe the transfer of manual annotations using curator
judgment to annotations associated with the ISS code. A
second example is GO_REF:0000036 (http://www.geneon
tology.org/cgi-bin/references.cgi#GO_REF:0000036),
‘Manual annotations that require more than one source of
functional data to support the assignment of the associated
GO term.’ This GO reference is used with the Inferred by
Curator (IC) evidence code, described below. GO references
are created and published on the GOC Web site (http://
www.geneontology.org/cgi-bin/references.cgi) only once
the biocurators agree on the content of the abstract and
its usage.
How to define an annotation?
Once literature relevant to a gene product has been iden-
tified, the following guidelines can be used to decide which
GO term(s) and evidence code(s) should be associated.
Individual articles may not provide results that support an-
notations for all three aspects of the ontology; thus, anno-
tations to the different aspects will generally need to come
from different articles. Also it is common, from a single
article, to identify multiple annotations identified for one
aspect and to annotate to different levels of granularity in
the same branch of the ontology. The granularity of the GO
term selected depends heavily on the type of experiments
being reported as well as the ability of the biocurator to
understand the limitations of that experimental method.
MacCullen (19) interviewed biocurators from the GOC in
.............................................................................................................................................................................................................................................................................................
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an effort to correlate the curator’s education, work experi-
ence and research experience to measured variability in an-
notation. After observing there was significant variability in
a test set of annotations, he explored possible causes.
MacCullen reported no correlation between the amount
of variation and any specific characteristic of the biocura-
tor’s education or experience and suggested that biocura-
tors should continually work to coordinate annotation
methods with the goal of minimizing variation. The solu-
tion used by the Consortium’s member projects is to have
continuing education and discussions between biocurators
to reduce variability that arises from inconsistent use of the
rules and misunderstanding of the ontology terms. Also to
further address the variability in the interpretation by bio-
curators, the GOC holds regular controlled annotation ex-
ercises to define standards and maintain consistent
procedures. These exercises are conducted within and
across most projects where biocurators annotate the same
article or a small set of articles and then compare their an-
notations. A discussion follows where the GOC comes to a
consensus about the most appropriate annotations for that
article and in the process educates its staff.
Choosing the right GO term
As emphasized above, ontology terms should be chosen
based not on the term name, but on the definition of the
term. Ontology terms can be explored using AmiGO (20),
http://amigo.geneontology.org, or QuickGO (21), http://
www.ebi.ac.uk/QuickGO/. Often it is hard to find the appro-
priate GO term using the description or phrases from the
literature because GO terms can be more descriptive and
they reflect the actual function or process rather than a
gene product name or family name. Therefore, to assist in
searching, and to accurately reflect the language of biology,
many ontology terms are associated with synonyms, which
are typically the terminology or language used in the litera-
ture. For example, the phrase ‘transcription repressor’ is
loosely used in the literature to refer to any transcription
repressing role. This concept is represented in the GO as
‘negative regulation of transcription, DNA-dependent’
[GO:0045892], and the phrase transcription repressor is a
synonym of this term. Development of the ontologies (i.e.,
adding new terms, refining definitions) is an active process
and if an appropriate GO term that is suitable to describe a
gene product is not available, biocurators are encouraged to
request that a new term be added to the ontology. The GOC
has setup several ways to handle new term requests and to
evaluate existing terms. The easiest way is to contact the GO
helpdesk (go-helpdesk@geneontology.org or http://www.
geneontology.org/GO.contacts.shtml) providing as much
detail as possible.
What if nothing is known about
the gene product?
Typically after an organism’s genome sequence is deter-
mined, structural annotation is performed using computa-
tional methods to make gene model predictions. Some of
the resulting predicted genes will have been previously
characterized and as a result will have literature-associated
evidence or sequence based relationships to other well-
defined genes. For other predicted genes neither experi-
mental nor sequence based functions will be available.
This represents sets of similar proteins that have yet to be
characterized and proteins without similarity to any previ-
ously characterized sequence. Thus no literature is available
on which to base an annotation. In cases such as this where
nothing can be gleaned from the literature, it is correct to
associate the gene product to the most general terms in the
three ontologies, ‘molecular_function’ (GO:0003674), ‘bio-
logical_process’ (GO:0008150) and ‘cellular_component’
(GO:0005575) (called the root nodes, see Table 1) with the
evidence code No Data (ND). It should be noted that anno-
tating to the root node specifically states that an extensive
search of the literature was conducted and no experimental
results were found to indicate the function of this gene
product. Since a biocurator infers that nothing has been
published about the gene product, a custom reference
(not a published article) that documents this curatorial pro-
cedure (the ‘GO reference’ GO_REF:0000015) should be
included in a ND annotation. These ND annotations are
used by projects such as SGD that have hunted through
the published literature for reported functions of all gene
products in the budding yeast. In this way the users can
trust that a literature search did indeed occur. The use of
ND is important because the absence of an annotation
could mean that a function has been reported but no GO
annotation has been captured or that there is no evidence
available. Annotation projects should routinely explore any
newly published works describing genes in their area of
interest to determine if any new experimental results are
available. Once new annotations have been defined, exist-
ing ND annotations for that gene product should be
removed.
It is especially important that biocurators make sure the
results presented in the article fit all parts of the term def-
initions; biocurators should not rely only on the term name.
In the following, we present guidelines for commonly en-
countered curation issues observed for the individual
ontologies.
Molecular function
Molecular Function describes activities, such as catalytic,
binding or transporter activities, at the molecular level
.............................................................................................................................................................................................................................................................................................
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(e.g. ‘protein kinase activity’ [GO:0004672], ‘6-phosphofruc-
tokinase activity’ [GO:0003872], ‘transcription factor bind-
ing’ [GO:0008134], ‘alanine transmembrane transporter
activity’ [GO:0022858], see Table 1 for GOIDs and defin-
itions for these GO terms). GO molecular function terms
describe activities rather than the entities (complexes,
gene products or molecules) that perform the actions.
Typically direct assays such as enzyme kinetics measure-
ments or binding studies can be used to infer molecular
function annotations. In addition sequence comparison
methods are often used to predict the molecular function
of a gene product because functions are often associated
with conserved protein domains (see Figure 2 to compare
evidence from experimental and nonexperimental results).
 Deciding between a Molecular Function and a
Biological Process term takes practice. The key question
to ask when selecting a Molecular Function term is
whether the experimental results show ‘how’ the
gene product accomplishes its role. For example if the
result simply shows that a mutant version of a gene
product affects transcription, by itself that doesn’t
show that the gene product is a transcription factor.
If instead the study shows that transcription is modu-
lated when the gene product binds to DNA or protein,
then an appropriate Molecular Function term (‘se-
quence-specific DNA binding RNA polymerase II tran-
scription factor activity’ [GO:0000981] or one of the
child terms of ‘protein binding transcription factor ac-
tivity’ [GO:0000988]) would be correct. In contrast, data
from a mutant phenotype experiment could be used to
make a Biological Process annotation to the term, ‘tran-
scription, DNA-dependent’ [GO:0006351] or to one of
its child terms (see Table 1 for GOIDs and definitions).
 Only GO terms that can be supported by the experi-
mental results should be selected, based on the GO
term definitions. For example, if the Introduction of
an article states that a gene product is a transcription
factor but only provides experimental results showing
DNA binding, then this article is not appropriate for an
experimentally based annotation to ‘sequence-specific
DNA binding RNA polymerase II transcription factor
activity’ [GO:0000988]. The appropriate term would be
‘sequence-specific DNA binding’ [GO:0043565] (see
Table 1) or a more specific DNA binding term. In
another situation, if the authors show via sequence
comparison methods that a protein is a serine/threo-
nine/tyrosine kinase, but only show experimental evi-
dence for phosphorylation of serine and threonine,
the biocurator must only annotate to ‘protein serine/
threonine kinase activity’ [GO:0004674] using an experi-
mental evidence code (example Inferred by Mutant
Phenotype or Inferred by Direct Assay, see Figure 2).
The biocurator could add an annotation to the protein
serine/threonine/tyrosine kinase activity with ISS evi-
dence code, see below. These annotations thus indicate
what was experimentally shown in an article and what
was predicted from sequence comparison.
 The Molecular Function ontology also contains terms
that describe protein–protein interactions. However,
annotating to such terms, e.g. ‘protein binding’
[GO:0005515], is done with careful consideration, as
most proteins bind other proteins at one time or an-
other. A rule of thumb is to determine whether the
gene product being annotated is accomplishing a bio-
logical purpose by binding to another protein: if so,
protein binding could be one of its functions. If more
specific information on the type of protein being
bound is available then the annotation should be
made to a more specific term. For example, if the
gene product being annotated binds to a histone,
then ‘histone binding’ [GO:0042393] is the appropriate
term.
 Many terms in the Molecular Function ontology impli-
citly or explicitly imply the binding of a chemical or
protein. In these cases, it is unnecessary to co-annotate
the binding of the substrates, cofactors or products, as
the enzymatic activity is defined by the compounds
being bound, if only in a transition state. For example,
while annotating to terms like ‘ATPase activity’
[GO:0016887] it is implicit that the gene product binds
to ATP and thus it is not necessary to annotate to both
‘ATPase activity’ and ‘ATP binding’ [GO:0005524].
Biological process
Biological Process describes biological goals accomplished
by one or more ordered assemblies of molecular functions.
A biological process is not equivalent to a pathway.
Specifically it does not represent any of the dynamics or
dependencies that would be required to describe a path-
way. Examples of broad Biological Process terms include
‘metabolic process’, ‘signaling’ and ‘death’. High-level pro-
cesses such as ‘cell death’ [GO:0008219] can have both sub-
types, such as ‘apoptotic process’ [GO:0006915], and
subprocesses, such as ‘apoptotic chromosome condensa-
tion’ [GO:0030263] (see Table 1). Experiments describing
the phenotypes of mutant genes, genetic interactions and
some in vitro assays, can all be informative about the bio-
logical processes in which a gene product participates
(Figure 2).
 On occasion when authors present experimental results
for a gene product’s role in a specific type of process,
they then extrapolate to infer its role in other related
processes. The annotations made from a given article
should only be for the processes experimentally
.............................................................................................................................................................................................................................................................................................
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demonstrated in that study. For example, if the results
show that a gene product can transport serine and
threonine, but the authors extrapolate that the gene
product can thus transport any amino acid, the gene
product should be annotated only to ‘serine transport’
[GO:0032329] and ‘threonine transport’ [GO:0015826]
and not to ‘alanine transport’ [GO:0032328], etc.
 Similar to the above example, if the results show a re-
sponse to a variety of stress conditions, it is best to
capture that data with the specific terms rather than
annotating to a higher-level term. For example, the
Saccharomyces cerevisiae gene HSP12 is annotated to
specific terms ‘cellular response to heat’ [GO:0034605],
‘cellular response to osmotic stress’ [GO:0071470] and
‘cellular response to oxidative stress’ [GO:0034599] (22)
rather than the high level ‘cellular response to stress’
[GO:0033554]. Grouping terms such as ‘cellular response
to stress’ are discouraged from use in direct annotations
because an experiment would typically not describe the
response to a global stress, but would rather test the
response to a specific type of stress.
 Direct versus indirect effect. Many GO Biological Process
annotations are assertions based upon mutant pheno-
types. When annotating based upon mutant phenotype
results, it can be difficult to discern if a gene product is
directly involved in the process for which the authors
screened (assayed) or if its absence instead results in
an indirect or downstream effect. For example if any
of the S. cerevisiae proteins involved in ‘RNA splicing’
[GO:0008380] are mutated, translation is affected. This
is a downstream effect because most of the genes
encoding ribosomal proteins have introns (example,
yeast ribosomal genes RPL2A, RPL2B, RPS11A, RPS11B)
and if splicing genes are mutated, these ribosomal
genes are not processed thereby affecting ribosomal as-
sembly and hence translation. In this case the genes
involved in splicing shouldn’t be annotated to ‘transla-
tion’ [GO:0006412]. Determining if a mutant phenotype
reflects a direct or indirect effect requires general under-
standing of the gene products as well as the biological
process under investigation. However, in cases where
little is known about the gene product or process, or
what is known is not easily reconciled with a mutant
phenotype, it is the responsibility of the biocurator to
accurately reflect the conclusions made from the avail-
able experiments. Such annotations should be revisited
when new literature becomes available and should be
replaced with a more specific term(s) if possible.
Figure 2. GO Evidence code decision tree describing the process of choosing an evidence code. This flow chart is meant to orient
the biocurator on the different categories of evidence codes and does not include the complete definitions of the evidence codes
(Table 2). This chart will aid the biocurator to evaluate the reported method or results and map them to an appropriate evidence
code; the biocurator should consult the detailed evidence code documentation available online from http://www.geneontology.
org/GO.evidence.shtml.
.............................................................................................................................................................................................................................................................................................
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 Annotating from gene or protein expression studies.
There are many expression studies that measure the
levels of RNA molecular species or protein levels when
an organism or cell line is exposed to various stimuli.
Conclusions from these experiments can suggest that
the over-expressed genes or proteins are involved in ‘re-
sponding to that stimulus’. However, overexpression
does not necessarily imply that those genes or proteins
are directly involved in the ‘response to the stimulus’
[GO:0050896]. The ‘response to’ GO terms are intended
to annotate gene products that are required for the re-
sponse to occur and are a direct result of the organism’s
reaction to the stimuli (e.g. production of a gene prod-
uct used to degrade a toxin or signaling to initiate
immune cell division in response to a parasite). If nothing
else is known about the gene product, it is acceptable to
annotate to a child of ‘response to stimulus’ using the
IEP evidence code. If more is known about the regula-
tion of the gene product, then that should be taken into
account to make a decision about annotating to the ‘re-
sponse to’ term. It is acceptable to not annotate from
such expression studies since changes in expression of a
gene product does not in itself indicate its contribution
to the function or process. Also, expression studies can
seldom support annotations to a Cellular Component or
Molecular Function term. Thus IEP should be used to
annotate to terms in Biological Process only.
 Annotating to regulation terms in Biological Process.
Regulation of a biological process is defined as a role
that modulates the frequency, rate or extent of that
process.
 To decide if the gene product participates directly in
a process or regulates that process, the nature of the
process should be studied carefully (Is there a defined
pathway? Is it a biochemical pathway and have the
gene products that perform the individual steps been
identified? Does the gene product being annotated
function within the pathway or outside of the path-
way to start or stop or change the rate of the
process?)
 If it cannot be determined whether the gene product
is involved in the process itself or instead in regula-
tion of the process (this can happen if the process is
not well defined), then biocurators should annotate
to the parent process term. For example, if a mutant
phenotype shows that a specific process is missing in
an organism but the nature of the function of the
gene product is unknown, an annotation should be
made to the parent process term. Note that processes
in GO are defined to reflect the predominant com-
munity view with respect to what is included in the
process and what is influencing or regulating the pro-
cess externally.
 Some gene products can be annotated to both a pro-
cess and regulation of that process as in the case of
positive and negative feedback loops.
Cellular component
Cellular Component describes locations, at the levels of sub-
cellular structures and macromolecular complexes.
Experiments informing Cellular Component annotations in-
clude fluorescence microscopy and co-fractionation of com-
plex members. Examples of cellular components include
‘nuclear inner membrane’ [GO:0005637], with the synonym
‘inner envelope’, and the ‘ubiquitin ligase complex’
[GO:0000151] (see Table 1), with several subtypes of these
complexes represented.
 Care must be taken when interpreting a subcellular lo-
cation, as certain tagged proteins may be mistargeted.
For example, in Huh et al. (23), (see their
Supplementary Table S2), the authors list several yeast
proteins that were mislocalized to the vacuole or other
components upon addition of a molecular tag.
 When a macromolecular complex has been character-
ized, all subunits of the complex should be annotated
to an appropriate complex term in the Cellular
Component ontology (example, ‘spliceosomal complex’
[GO:005681] or ‘nucleosome’ [GO:0000786]). Depending
on the nature of the experiment, annotation to a com-
plex can either be made using the IDA evidence code or
the IPI evidence code. For example, if an author purifies
a complex and then investigates the constituent gene
products, a curator would use the IDA evidence code
for annotation. If the authors instead perform protein-
binding assays to show that a gene product binds to
other members of the complex, then the IPI evidence
code should be used with appropriate targets included
in the WITH/FROM column (see below).
 There are several terms in the Cellular Component
ontology in the format ‘x part’ (e.g. ‘nuclear part’
[GO:0044428]; ‘membrane part’ [GO:0044425] etc.).
These terms were added to make the ontology is_a
complete (i.e. ontologically correct). Without additional
qualifiers, annotation to these terms conveys no more
information than annotation to the parent terms.
Hence, these terms should not be used in making
manual annotations.
Additional information about the
GO term (annotation extensions)
Often, an article will contain more detailed information
than existing GO terms can fully represent. In many such
cases, biocurators may request new more specific terms to
.............................................................................................................................................................................................................................................................................................
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be added to the ontology, but new GO terms may not
always be the preferred solution. Rather, some informa-
tion, such as the substrates of a protein kinase or the cell
type in which a gene product has a particular localization, is
best-captured using annotation extensions (also referred to
as ‘column 16’ after its position in the GAF, Table 3).
Additional information captured in this column provides
more biological context to the GO annotation.
An annotation extension has two parts: an entity identi-
fier for the object that is used to increase the specificity of
the annotation (e.g. identifiers for a gene, gene product,
GO term or a term from an external ontology such as a cell
type or anatomy ontology), and a relation that connects
the ‘primary’ GO term to the entity represented by the
identifier. The information captured in GO annotation ex-
tensions encompasses several types of effector–target
relationships.
 The substrates of a function such as the target of a
protein kinase. For example, the S. pombe win1
(SPAC1006.09) protein has been annotated to ‘MAP
kinase kinase kinase activity’ [GO:0004709] with the ex-
tension ‘has_direct_input (pombase:wis1)’, where the
S. pombe protein wis1 is the substrate of win1.
 Activators and inhibitors, using the relationships activa-
ted_by and inhibited_by.
 Regulation targets of signaling pathways or transcrip-
tion factors. For example, the S. pombe gene map1 is
annotated to ‘positive regulation of mating-type spe-
cific transcription from RNA polymerase II promoter’
[GO:0001197] with the extension ‘has_regulation_target
(PomBase:SPMTR.02)’ indicating that SPMTR.02/matPi is
the target of the regulation event.
 Spatial aspects of processes or localizations, as in a spe-
cific cell or tissue type as represented in the Cell Type
Ontology (24), e.g. occurs_in [CL:0000182], where
CL:0000182 identifies the cell type ‘hepatocyte’.
 Temporal aspects of a process or developmental stage,
e.g. ‘happens_during’ for mitosis. For example, the
S. pombe gene mug27 is annotated to ‘septation initi-
ation signaling cascade’ [GO:0031028] with the exten-
sion ‘happens_during meiotic cell cycle’ [GO:0051321]
implying that mug27 is involved in septation initiation
signaling cascade that happens during meiotic cell cycle.
An annotation may have one or more extensions, using the
same or different relations. It is thus possible to capture
multiple substrates of a kinase, for example. Compound
extensions are also allowed, making it possible to indicate
that two or more extensions apply simultaneously. For ex-
ample, a gene product that is involved in a process only
when it localizes to the nucleus, and only during S-phase
of the cell cycle, can be annotated to a process term plus
the extension ‘occurs_in nucleus’, ‘during S phase of mitotic
cell cycle’. A list of allowed relationships are available in the
go_annotation_extension_relations.obo file (http://viewvc.
geneontology.org/viewvc/GO-SVN/trunk/ontology/extensio
ns/go_annotation_extension_relations.obo) while the
format for the various database identifiers can be found
in the GO cross reference file (http://www.geneontology.
org/doc/GO.xrf_abbs) (manuscript in preparation).
Choice of evidence code
Four different categories of evidence codes are available
for manual curation: experimental, computational analysis,
author statements and curatorial statements (details in
Table 2, Figure 2).
 Use of an experimental evidence code indicates that
the cited article reported results that support the asso-
ciation of a GO term from characterization of a gene or
gene product.
 Evidence codes in the computational analysis category
imply that the annotation was inferred based on
in silico analysis of the gene or gene product sequence
and/or other data as cited in the reference.
Biocurators can also perform in silico analysis, inde-
pendent of a published article, to infer an annotation,
in which case a GO Reference (GO_REF) that describes
the methods used by the biocurator is used as
reference.
 Author statements include assertions made anywhere in
the cited article, including the Introduction and
Discussion. These evidence codes were made available
by the GOC because during the initial stages of the
project; curation of such statements was an easy way
to get a good volume of annotations quickly. However,
annotations using these evidence codes are now being
replaced by those citing direct evidence. Use of author
statement codes is discouraged and so they are not
described in detail here.
 Curatorial statements indicate that the biocurator re-
viewed the information and made the appropriate an-
notation decision. IC and ND are curatorial statement
codes. The ND evidence code, which has been described
earlier in the article, is used to indicate that there is no
biological data available to infer any GO term for that
gene product. The IC evidence code can be used in two
different scenarios. The first case includes those in-
stances where an annotation is not supported by any
direct evidence, but can be reasonably inferred by a
biocurator from other GO annotations, for which evi-
dence is available. For example, if a gene product is
shown experimentally to have the function of ‘se-
quence-specific DNA binding RNA polymerase II tran-
scription factor activity’ (GO:0000981), and there is no
direct evidence for the cellular location of the gene
product, then it is within general knowledge that this
.............................................................................................................................................................................................................................................................................................
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function takes place in the nucleus and thus the bio-
curator can infer the gene product’s location. Both an-
notations will use the same published article as
reference and in addition the IC annotation will include
the GOID used by the biocurator for the inference in
the FROM (column 8 in the GAF 2.0 file, Table 3). In the
second case, a curator infers an annotation based on
evidence from multiple sources of evidence/GO annota-
tion as described below.
Data supporting the evidence code
In addition to the evidence code that reflects the type of
experiment leading to an annotation, the GOC provides
two ways to capture additional evidence information for
an annotation: the qualifier and the WITH/FROM column.
A qualifier can be used to augment the interpretation of
the GO term. Three qualifiers are available: colocalizes_
with, contributes_to and NOT. These are found in the
QUALIFIER column of the GAF 2.0 format (Table 3).
QUALIFIER
 Sometimes, gene products are transiently or peripher-
ally associated with an organelle or complex. These re-
sults can be annotated to the relevant Cellular
Component term along with the colocalizes_with quali-
fier. The colocalizes_with qualifier can be used only
with the Cellular Component ontology. For example,
the S. pombe protein clp1 is a nucleolar protein but
transiently associates itself with the ‘actomyosin con-
tractile ring’ [GO:0005826] (25). Hence clp1 is annotated
to this term with the colocalizes_with qualifier.
 The contributes_to qualifier can be used only with
Molecular Function terms. Sometimes complexes are
shown to have an activity, but the activity of each sub-
unit is not shown. In such cases, individual subunits that
are part of a complex can be annotated to terms that
describe the function of the complex. If the activity of
the complex is associated with a single subunit and the
other subunits serve either as regulatory subunits or to
keep the complex together, then the subunits should
be annotated to those specific activities. Contributes_to
is not needed to annotate a catalytic subunit.
Furthermore, contributes_to may be used for any
noncatalytic subunit, whether the subunit is essential
for the activity of the complex or not. In another
usage, if two or more subunits of a complex are
required for the catalytic activity of the complex, then
all those subunits get annotated to the corresponding
Molecular Function term with the contributes_to quali-
fier. The gene products annotated to function terms
with the contributes_to qualifier should also be
annotated to the complex term in the Cellular
Component that has that molecular function. For ex-
ample, the subunits of the S. cerevisiae mitochondrial
respiratory chain complex III are all annotated to the
Molecular Function term ‘ubiquinol-cytochrome-c re-
ductase activity’ [GO:0008121] with the contributes_to
qualifier (26) and to the complex term ‘mitochondrial
respiratory chain complex III’ [GO:0005750] in the
Cellular Component ontology. This qualifier is not
used with terms in Biological Process ontology because
biological processes are a collection of molecular events
and by default gene products contribute to the whole
process.
 The negative of a GO term, the NOT qualifier. This
qualifier is used to explicitly denote that the gene prod-
uct is not associated with the function, process or com-
ponent represented by the GO term. This qualifier is
used when a gene product is expected to have a func-
tion, but has been shown experimentally not to have
the enzymatic activity; in this case the gene product can
be annotated as NOT. For example, the NOT qualifier is
used to indicate that the Caenorhabditis elegans gene
C42C1.11a.2 was experimentally shown to NOT have
‘leukotriene-A4 hydrolase activity’ [GO:0004463] despite
strong homology to the human leukotriene A4 hydro-
lase (27). Annotations that use the NOT qualifier can be
particularly informative for evolutionary studies that
wish to explore the gain and/or loss of gene product
activity.
WITH/FROM column
 The WITH column is required for Inferred from
Electronic Annotation (IEA), IGI, IPI, ISS, Inferred from
Sequence Alignment (ISA) and Inferred from Sequence
Orthology (ISO) codes (Table 2).
 For example, when using ISS, the WITH column should
be used to indicate the identifier of the gene product
used for the sequence or structural comparison. For
annotations based on sequence comparisons, it is im-
portant to confirm that the protein used for the
sequence comparison was experimentally verified to
have that function and has a GO annotation reflecting
that experimental finding. If a GO annotation is
missing please report this to the GO consortium
(go-helpdesk@geneontology.org).
 Likewise, for IPI and IGI codes, the WITH column should
be used to indicate the interacting gene product or
gene respectively. Multiple identifiers can be entered
in this field.
 The FROM value is used to provide supporting infor-
mation for the IC evidence code. For example if
a Molecular Function annotation is made to
.............................................................................................................................................................................................................................................................................................
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‘sequence-specific DNA binding RNA polymerase II tran-
scription factor activity’ [GO:0000981] with experimen-
tal evidence, and a biocurator deduces that the gene
product thus resides in the nucleus, then the compo-
nent annotation to nucleus is made with the FROM
value GO:0000981.
 In many cases a GO term can be inferred from just one
other annotation, but occasionally a curator can also
infer an annotation to a term based on evidence
from multiple sources of evidence/GO annotation. The
FROM value in these annotations will therefore supply
more than one GO identifier, obtained from the set of
supporting GO annotations assigned to the same gene/
gene product identifier which cite publicly available ref-
erences and the annotation would have an unpublished
GO reference (GO_REF:000036) in its Reference field.
Suggested reading
For examples of how GO annotations have been developed
and how these guidelines have been put into practice
please consult the following articles. The work on biofilm
and filamentous growth in Candida (28), heart develop-
ment (29), a case study of focused curation for renal and
cardiovascular research (30) and in depth curation of the
peroxisome proteome in humans (31) will be instructive for
learning about curation of the literature to create GO
annotations.
Conclusions
The goal of the GOC is the unification of biology by creat-
ing a nomenclature used for describing the functional char-
acteristics of any gene product, protein or RNA, from any
organism. The GOC provides the research community a
comprehensive resource of functional information on
gene products. Toward this end, the GOC provides ontolo-
gies, guidelines to make the gene product-to-GO term as-
sociations and standardized formats to publish these
annotations. This guide describes the methods used to
create one of the two types of annotations that can be
made with GO terms: manual curation. Consistency of GO
annotations is paramount to ensure the quality of any ana-
lysis using the annotations. An understanding of the re-
quirements and strategies associated with the three
aspects of the GO with those of the different evidence
codes can ensure manual annotations will be an accurate
representation of the published results. Our hope is that
these guidelines will provide encouragement and assist-
ance to researchers to annotate their favorite gene prod-
ucts, enriching both the quality and quantity of GO
annotations available via the GOC.
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